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Is it Time for a New Paradigm in
Calciﬁc Aortic Valve Disease?*
David S. Owens, MD, Catherine M. Otto, MD
Seattle, WashingtonAt an average heart rate of 70 beats/min, the aortic
valve in a 70-year-old patient will have opened and
closed, incessantly, over 25 million times. It is not
surprising then that calcific aortic valve disease
(CAVD), which becomes clinically apparent only
late in life, was previously considered a degenerative
process. Now, CAVD is known to be—on the basis
of research over the past 2 decades, including
histopathologic, epidemiologic, and animal stud-
ies—a complex, biologically active process with
many mechanistic similarities to atherosclerosis but
also with key differences. Yet despite this recent
understanding, valve replacement surgery remains
the only proven therapy for this disease.
See page 919
It is not coincidental that advances in CAVD
biology paralleled advances in noninvasive imaging.
Two-dimensional echocardiography enables direct,
in vivo visualization of valve anatomy and provides
semiquantitative measures of calcification severity.
Doppler echocardiography is clinically indispensible
in determining the hemodynamic consequences of
late stage disease (aortic stenosis) and optimal
timing of operative interventions. However, as im-
portant as echocardiography has been for under-
standing CAVD, it is limited in its ability to
monitor the progression of early-stage, pre-
obstructive CAVD (aortic sclerosis). Fortunately,
complementary imaging modalities are starting to
arise. For example, computed tomography is a
well-validated tool for quantifying early-stage cal-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the University of Washington, Seattle, Washington.cification and measuring progression, although at
the expense of radiation exposure.
Large population-based studies such as the
echocardiography-based CHS (Cardiovascular
Health Study) study (1) and the computed
tomography-based MESA (Multi-Ethnic Study of
Atherosclerosis) study (2) have identified risk asso-
ciations between CAVD and several clinical factors,
although it is notable that CAVD was not a
pre-specified end point for these trials. Many of
these risk associations are also coronary artery dis-
ease risk factors: age, male sex, hypertension, hy-
percholesterolemia, the metabolic syndrome, and
smoking. Strengthening the paradigm that CAVD
is due to an atherosclerosis-like mechanism are
histopathologic studies showing cellular inflamma-
tion and lipoprotein deposition and hypercholester-
olemic animal models of aortic sclerosis.
A natural corollary of the paradigm that CAVD
is an atherosclerosis variant was the hypothesis,
supported by retrospective analyses, that CAVD
progression could be slowed by the same interven-
tions that slow coronary artery disease progression.
Yet 2 large randomized clinical trials of statin
medications—SALTIRE (Scottish Aortic Stenosis
and Lipid Lowering Trial, Impact on Regression)
(3) and SEAS (Simvastatin and Ezetimibe in Aor-
tic Stenosis) (4)—failed to slow CAVD progression
or delay the clinical sequelae of CAVD in older
adults with mild to moderate or more advanced
CAVD. It is possible that these trials targeted
patients whose disease was too advanced for therapy
to be effective, but identifying patients in earlier
stages is challenging and would require treating
many patients who would never develop clinical
disease. In light of the negative results of these
large, well designed studies, a new paradigm for
CAVD might be needed.
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929Although there are mechanistic similarities be-
ween atherosclerosis and CAVD, CAVD is not
imply atherosclerosis of the valve. Clinicians see
any patients with severe aortic stenosis that have
ittle coronary atherosclerosis at the time of valve
eplacement. Whereas the hallmark of atheroscle-
osis is the unstable lipid-rich plaque, the hallmark
f CAVD is severe, progressive calcification that
tiffens leaflets and leads to hemodynamic obstruc-
ion. More detailed explorations of the nonathero-
clerotic mechanisms that contribute to CAVD—
uch as shear forces, genetic factors, and regulators
f myofibroblast differentiation and osteoblastic
alcium deposition—are clearly needed. This need
as highlighted in a recent study by Miller et al. (5)
howing that not only are reactive oxygen species
ROS) increased in calcifying aortic valve leaflets
ut the primary mechanism of ROS production,
ncoupled nitric oxide (NO) synthase activity,
ight be distinct from that seen in vascular athero-
clerotic lesions.
The study by Ngo et al. (6) in the current issue of
JACC represents a welcome departure from study-
ng only traditional CAVD risk associations. Two
spects of this study merit special comment. First,
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Figure 1. A Potential Paradigm for Understanding CAVD Progre
In early stage calciﬁc aortic valve disease (CAVD), traditional cardiov
mechanisms. Increased valvular oxidative injury causes transcription
ways, promoting myoﬁbroblast transdifferentiation into osteogenic
calcium homeostasis, and dystrophic epitaxial calciﬁcation play an i
phology (e.g., bicuspid valves), and shear stress likely contribute to
abolic syndrome; NOS  nitric oxide synthase.he use of integrated backscatter of the aortic valve
eaflet as a quantitative measure of aortic sclerosis
everity is novel. It is somewhat difficult to interpret
he apparent lack of association between CAVD
nd atherosclerotic risk factors, given the use of this
ewer echocardiographic approach, the small sam-
le size, and high degree of disease misclassifica-
ion. However, although this method needs addi-
ional validation, it offers potential for a new means
f quantifying CAVD in its early stages.
Second, they explore the relationship between
AVD and several indirect measures of NO re-
ponsiveness, including asymmetric dimethylargin-
ne (ADMA) concentration—a marker of endothe-
ial dysfunction—and platelet NO resistance.
alvular calcification is a complex interplay between
ocal paracrine factors and systemic regulators of
alcium homeostasis. Oxidative stress seems to play
central role in this process, with ROS mediating
ranscriptional upregulation of the Wnt/-catenin,
unx2/Cbfa1, and Msx2 pathways that promote
steochondrogenic matrix remodeling and myofi-
roblast transformation toward osteoblastic pheno-
ypes. As the Miller et al. study (5) highlights, the
rinciple mechanisms of ROS production might be
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pregulation of the Wnt/-catenin, Runx2/Cbfa1, and Msx2 path-
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asing role as calciﬁcation progresses. Genetic factors, valve mor-
ase progression across the full spectrum of disease. MetS  met-h
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930issue-specific, with uncoupled NO synthase activ-
ty playing a central role in the production of
alvular ROS. But calcification can also occur
hrough noncellular mechanisms by means of epi-
axial calcification, and both osteopontin and fe-
uin—local and systemic inhibitors of calcifica-
ion—might be important regulators of this process.
The positive finding of an association between
ortic valve integrated backscatter intensity and
latelet NO resistance is intriguing. It is possible
hat the systemic or genetic mechanisms underlying
latelet NO resistance (e.g., scavenging of NO by
uperoxide species) are associated with increased
OS within the aortic valve leaflets. Additionally,
latelet NO serves as an inhibitor of platelet aggre-
ation, and NO resistance implies a pro-thrombotic
ilieu for CAVD patients. It has been previously
hown that aortic sclerosis is associated with a 50%
ncreased risk for cardiovascular morbidity and
ortality (7), a finding that has been attributed to
ubclinical atherosclerosis, inflammation, or otherlation 2006;113:2113–9. nisms contributes tother potential mechanism: underlying NO resis-
ance might predispose to both valvular calcification
nd thrombotic events. Additional confirmatory
nd mechanistic studies are clearly needed.
Over the next several decades, as the population
f the U.S. and the world ages, CAVD will become
ncreasingly prevalent and clinically manifest. Al-
hough we now know that CAVD is a biologically
ctive process with many similarities to atheroscle-
osis, the atherosclerosis paradigm has failed to
dentify effective medical therapies to slow or pre-
ent CAVD progression. If such therapies are to be
eveloped, it is time for a new paradigm (Fig. 1) to
timulate new thinking and new insights into the
aried and overlapping mechanisms that regulate
esion formation, myofibroblastic transformation,
nd calcification progression.
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